A study recently published by the International Journal of Chronic Obstructive Pulmonary Disease (COPD), analyzes current recommendations for palliative care (PC) for chronic obstructive pulmonary disease (COPD) patients to determine their level of reliability during an expected 1-year mortality.
PC is typically used for patients with neoplastic diseases and may be used with other therapies to improve symptoms and the overall quality of life. PC has proven to be effective in COPD, but it is more complicated in utilization.
"One of the main barriers for initiating PC in COPD is the unpredictability of vital prognosis in an individual patient," the authors wrote. "Many COPD patients present a gradual deterioration, others stability for years, while a subgroup suffers acute COPD exacerbations."
The study involved 3 main phases to determine the reliability of PC for COPD patients:
Of the 697 patients hospitalized for COPD exacerbation included in the study, 93% were males and had a 1-mortality rate of 17.5%. However, of those whom met the criteria for PC, there was not a statistical significance in mortality differences.
“The main conclusion of our study is that none of the suggested criteria for initiating PC based on an expected poor vital prognosis in COPD patients in the short or medium term offers sufficient reliability, and perhaps, they should be avoided as exclusive criteria for considering PC or at least critically evaluated,” the authors concluded.
Despite the lack of statistical differences, the researchers suggested that the decision to begin PC should be paired with restorative care. Furthermore, PC is often associated with only being necessary for terminal care, but the study recommended considering its applicability when used with other therapies.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More